XML 28 R18.htm IDEA: XBRL DOCUMENT
v3.21.2

SHAREHOLDERS’ EQUITY | 6 Months Ended
--- | ---
Jun. 30, 2021
Equity [Abstract] |
SHAREHOLDERS’ EQUITY | 11. SHAREHOLDERS’ EQUITY Common Stock At June 30, 2021, the Company had 4,676,301 shares of common stock outstanding. On February 17, 2021, the Company sold 1,131,600 shares of common stock for net proceeds of $5.3 million. Warrants In December 2016, the Company completed a registered direct offering of 100,000 shares of common stock at a net gross price of $15.00 per share. Concurrently, the investors received warrants to purchase 100,000 shares of common stock of the Company at an exercise price of $20.05 per share, for a period of five years from the final closing date of June 21, 2017. The warrants include anti-dilution rights. The total net proceeds received by the Company were approximately $1.3 million. The fair value of the warrants upon issuance were $1.2 million, with the remaining $0.1 million being attributed to common stock. On September 29, 2020, the Company received proceeds of $565 thousand related to the exercise of warrants to purchase 50,000 shares of common stock. The warrants have been classified as liabilities due to features in the warrant agreement that give the warrant holder an option to require the Company to redeem the warrant at a calculated fair value in the event of a “Fundamental Transaction,” as defined in the warrant agreement. The fair value of the remaining warrants to purchase 50,000 shares of common stock was $119 thousand and $95 thousand at June 30, 2021 and December 31, 2020, respectively. Pursuant to the original warrant agreement, as a result of common stock issuances at various prices, the warrant exercise price has been reduced from its original $20.50 exercise price to the floor price of $3.92, which is the exercise price of the warrants at June 30, 2021. Stock Options From time to time, the Company may grant stock options under its incentive plan covering shares of common stock to employees of the Company. Stock options, when exercised, are settled through the payment of the exercise price in exchange for new shares of stock underlying the option. These awards typically expire ten years from the grant date. For the six months ended June 30, 2021 and 2020, there was no compensation expense related to stock options. As of December 31, 2019, all stock options had vested. No stock options were granted or exercised, during the six months ended June 30, 2021 or 2020. During the six months ended June 30, 2021 and 2020, options to purchase 332 shares and 166 shares, respectively, expired. Presented below is information about stock options outstanding and exercisable as of June 30, 2021 and December 31, 2020: SCHEDULE OF STOCK OPTIONS ACTIVITY
|  | June 30, 2021 |  |  | December 31, 2020 |
|  | Shares |  |  | Price |  |  | Shares |  |  | Price |
Stock options outstanding and exercisable |  |  | 31,035 |  |  | $ | 62.79 |  |  |  | 31,367 |  |  | $ | 64.78 |
The following table summarizes information for stock options outstanding and for stock options exercisable at June 30, 2021: SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE
Options Outstanding |  |  | Options Exercisable |
|  |  | Exercise Price |  |  | Weighted |  |  | Remaining |  |  |  |  |  | Weighted |
Number of |  |  | Range |  |  | Average Exercise |  |  | Contractual Term |  |  | Number of |  |  | Average Exercise |
Shares |  |  | Low |  |  | High |  |  | Price |  |  | (years) |  |  | Shares |  |  | Price |
| 16,500 |  |  | $ | 7.20 |  |  | $ | 11.60 |  |  | $ | 10.00 |  |  |  | 6.3 |  |  |  | 16,500 |  |  | $ | 10.00 |
| 10,622 |  |  |  | 90.00 |  |  |  | 124.80 |  |  |  | 106.20 |  |  |  | 2.8 |  |  |  | 10,622 |  |  |  | 106.20 |
| 2,913 |  |  |  | 139.20 |  |  |  | 171.00 |  |  |  | 147.39 |  |  |  | 1.0 |  |  |  | 2,913 |  |  |  | 147.39 |
| 1,000 |  |  |  | 226.20 |  |  |  | 226.20 |  |  |  | 226.20 |  |  |  | 3.2 |  |  |  | 1,000 |  |  |  | 226.20 |
| 31,035 |  |  | $ | 7.20 |  |  | $ | 226.20 |  |  | $ | 62.79 |  |  |  | 4.5 |  |  |  | 31,035 |  |  | $ | 62.79 |
Restricted Stock Company grants restricted stock under its incentive plan covering shares of common stock to employees and directors of the Company. The restricted stock awards are time-based awards and are amortized ratably over the requisite service period. Restricted stock vests ratably on each anniversary following the grant date provided the grantee is employed on the vesting date. Restricted stock granted to employees, when vested are net settled through the issuance of shares, net of the number of shares required to pay withholding taxes. The following table presents the changes in non-vested, time-based restricted stock awards to all employees and directors for the six months ended June 30, 2021: SCHEDULE OF NON-VESTED TIME-BASED RESTRICTED STOCK AWARDS
|  | Shares |  |  | Weighted-Avg. Grant Date Fair Value per Share |
Non-vested restricted stock at December 31, 2020 |  |  | 71,000 |  |  | $ | 4.89 |
Granted |  |  | 150,000 |  |  | $ | 4.72 |
Vested |  |  | (47,000 | ) |  | $ | 4.89 |
Non-vested at June 30, 2021 |  |  | 174,000 |  |  | $ | 4.75 |
The following table presents the stock compensation expense related to restricted stock grants for the three and six months ended June 30, 2021 and 2020: SCHEDULE OF STOCK COMPENSATION EXPENSE RELATED TO RESTRICTED STOCK GRANTS
|  |  |  | 2021 |  |  |  | 2020 |  |  |  | 2021 |  |  |  | 2020 |
|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
|  | (in thousands) |
Stock compensation expense |  | $ | 116 |  |  | $ | 64 |  |  | $ | 195 |  |  | $ | 106 |
Total compensation cost related to non-vested time-based awards not yet recognized in the Company’s condensed consolidated statements of operations as of June 30, 2021, is $650 thousand. This cost is expected to be recognized over a weighted average period of 2.6 years.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration